Welcome to our dedicated page for NanoString Technologies news (Ticker: NSTG), a resource for investors and traders seeking the latest updates and insights on NanoString Technologies stock.
NanoString Technologies, Inc. (NASDAQ: NSTG) is a renowned provider of life science tools for translational research and molecular diagnostics. Established in 2008, NanoString's technology is pivotal in enabling a diverse array of basic research, translational medicine, and in vitro diagnostics applications. The company's flagship product, the nCounter® Analysis System, is celebrated for its ability to profile the expression of hundreds of genes, miRNAs, or copy number variations simultaneously with high sensitivity and precision. This system has been referenced in over 300 peer-reviewed publications, underscoring its widespread adoption and scientific credibility.
The nCounter® system's versatility extends to diagnostic use as the nCounter Dx Analysis System, further solidifying NanoString's footprint in the molecular diagnostics landscape. The technology stands out for its cost-effectiveness and efficiency, making it a valuable tool for applications such as biomarker discovery and validation, as well as other translational research endeavors.
Among recent developments, NanoString Technologies has been embroiled in significant litigation with 10x Genomics, Inc. Notably, the European Unified Patent Court (UPC) declined to issue a second preliminary injunction against NanoString, allowing the company to continue its operations in specific jurisdictions. However, injunctions from the Regional Court Munich I and the UPC still impose restrictions on the sale and service of NanoString's CosMx Spatial Molecular Imager (SMI) instruments and reagents for RNA detection in Europe.
The legal battles extend to the United States, where 10x Genomics has filed multiple suits against NanoString alleging patent infringement related to the GeoMx Digital Spatial Profiler and the CosMx SMI. Recently, a jury in the U.S. District Court for the District of Delaware awarded 10x Genomics over $31 million in damages, asserting that NanoString's GeoMx products willfully infringed on several patents.
Despite these legal challenges, NanoString continues to thrive as a leader in its field, providing essential tools that drive significant discoveries in oncology, immunology, neuroscience, and beyond. The company's commitment to advancing human health through molecular diagnostics and translational research tools remains unwavering.
NanoString Technologies, Inc. (NASDAQ:NSTG) has announced an upcoming Investor and Analyst Day scheduled for December 1st, from 11:30 AM to 1:30 PM Eastern time. The virtual event will provide an updated view of the total addressable market for spatial biology, an overview of the adoption of the GeoMx® Digital Spatial Profiler, and a review of the company’s technology roadmap for spatial biology. The presentations will be followed by a Q&A session with management. Interested parties can access the webcast on the company's website for 90 days.
NanoString Technologies (NASDAQ:NSTG) announced a collaboration with Oregon Health & Science University to develop novel GeoMx® Digital Spatial Profiler (DSP) protein assays aimed at enhancing breast cancer analysis. The collaboration is part of the GeoMx Translational Leadership Network and the GeoMx Clinical Consortium, focusing on clinical applications of the GeoMx DSP platform. The new assays will feature up to 30 targets and may improve patient outcomes through advanced pathology insights.
Pathologists will validate the assays for potential laboratory use, further expanding the capabilities of spatial biology in cancer care.
NanoString Technologies, Inc. (NASDAQ:NSTG) announced its participation in the Stifel 2020 Virtual Healthcare Conference, scheduled for November 16, 2020, at 4:00 PM ET. President and CEO Brad Gray will present, and interested parties can access the live webcast on the company's investor section. A replay will be available within an hour post-presentation and archived for 60 days. NanoString is recognized for its nCounter® Analysis System, widely used in life sciences research, and its GeoMx™ Digital Spatial Profiler for RNA and protein target profiling.
NanoString Technologies (NASDAQ:NSTG) announced highlights from over 35 related abstracts, featuring 11 spatial biology studies, at the SITC 35th Annual Meeting. The GeoMx Digital Spatial Profiler (DSP) plays a key role in immunotherapy research by analyzing immune-tumor interactions. Notable presentations include studies on advanced bladder cancer, combination therapies for HER2+ neoplasms, and predictive biomarkers in metastatic melanoma. The company will also host a CAR-T technology symposium featuring expert discussions on spatial and molecular profiling.
NanoString Technologies, Inc. (NASDAQ:NSTG) reported its Q3 2020 financial results, showcasing a 14% year-over-year growth in product and service revenue, totaling $30.1 million. Instrument revenue surged by 60% to $12.9 million, driven by strong sales of the GeoMx® Digital Spatial Profiler. However, consumables revenue declined by 11%. The company has a strong balance sheet, ending the quarter with $231.0 million in cash, having recently raised $215.8 million through a public offering. Management announced a virtual Investor Day on December 1, 2020.
NanoString Technologies, Inc. (NASDAQ:NSTG) has launched GeoMx® DSP Protein Assays for next generation sequencing (NGS) readout, enhancing multi-analyte analysis capabilities. The assays are designed for immuno-oncology applications, supporting over 50 targets. These new assays have demonstrated effective multi-plex performance on various tissue types, enabling researchers to compare protein expression levels with RNA results. Additionally, NanoString is introducing new 10-plex Mouse Immuno-Oncology Protein Assays for nCounter readout, expanding their portfolio to over 300 validated antibodies.
NanoString Technologies, Inc. (NASDAQ:NSTG) announced its participation in the 29th Annual Credit Suisse Healthcare Conference, scheduled for November 11, 2020, at 11:00am ET. CEO Brad Gray will present during this virtual event, which can be accessed via a live webcast on the company’s investor website. The presentation will be available for replay one hour post-event and archived for 60 days. NanoString is renowned for its nCounter® Analysis System, utilized in over 3,800 peer-reviewed publications, and its GeoMx™ Digital Spatial Profiler for advanced RNA and protein analysis.
NanoString Technologies (NASDAQ:NSTG) has successfully completed its underwritten public offering of 5,750,000 shares at $40.00 per share, generating $230.0 million in gross proceeds. The offering included the full exercise of the underwriters’ option to purchase an additional 750,000 shares. After deducting expenses, net proceeds are approximately $215.7 million. The funds will be allocated for working capital and general corporate purposes. J.P. Morgan, UBS, and Cowen led the offering, which was made under a shelf registration statement filed with the SEC.
NanoString Technologies (NASDAQ:NSTG) and OnRamp Bioinformatics have expanded their partnership to enhance analysis tools for the nCounter® Analysis System. Following a successful Early Access Program, new analysis features will now be available to all nCounter users via the ROSALIND platform. This updated capability enables faster data insights and improved collaboration among researchers, making it accessible for those without bioinformatics expertise. The integration aims to streamline research efforts and accelerate discoveries in life sciences.
NanoString Technologies (NASDAQ:NSTG) has announced an upsized public offering of 5,000,000 shares of its common stock, priced at $40.00 per share, aiming for gross proceeds of $200 million. This offering size was increased from the initially announced $150 million. Additionally, underwriters have a 30-day option to purchase up to 750,000 additional shares. The funds will be used for working capital and general corporate purposes, with the offering expected to close around October 13, 2020, pending customary conditions.
FAQ
What is the market cap of NanoString Technologies (NSTG)?
What is NanoString Technologies' primary business?
What is the nCounter® Analysis System?
What are some applications of NanoString's technology?
Has NanoString been involved in any legal issues recently?
What was the outcome of the recent lawsuit in the U.S. District Court for the District of Delaware?
What is the significance of the nCounter Dx Analysis System?
How many peer-reviewed publications have cited the nCounter® system?
What is the cost advantage of NanoString's technology?
What are the legal implications of the injunctions against NanoString in Europe?
How does NanoString contribute to advancements in human health?
